{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:55:43Z","timestamp":1789390543068,"version":"build-2803163510"},"reference-count":55,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","award":["Dean's Bequest"],"award-info":[{"award-number":["Dean's Bequest"]}],"id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003189","name":"Freemasons New Zealand","doi-asserted-by":"publisher","award":["Ph.D. Scholarship"],"award-info":[{"award-number":["Ph.D. Scholarship"]}],"id":[{"id":"10.13039\/501100003189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0270-1","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T08:44:47Z","timestamp":1502700287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer"],"prefix":"10.1136","volume":"5","author":[{"given":"Braeden","family":"Donaldson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Al-Barwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Pelham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"key":"270_CR1","unstructured":"Stewart BW, Wild C. International Agency for Research on Cancer & World Health Organization. World Cancer Report 2014. 2014."},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3109\/0284186X.2013.764008","volume":"52","author":"C Maringe","year":"2013","unstructured":"Maringe C, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000\u20132007. Acta Oncol. 2013;52:919\u201332. doi: 10.3109\/0284186X.2013.764008 .","journal-title":"Acta Oncol"},{"key":"270_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00262-015-1706-4","volume":"64","author":"JP Balint","year":"2015","unstructured":"Balint JP, et al. Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother. 2015;64:977\u201387. doi: 10.1007\/s00262-015-1706-4 .","journal-title":"Cancer Immunol Immunother"},{"key":"270_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-3-S2-P444","volume":"3","author":"MA Morse","year":"2015","unstructured":"Morse MA, et al. Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. J Immunother Cancer. 2015;3:1.","journal-title":"J Immunother Cancer"},{"key":"270_CR5","doi-asserted-by":"crossref","unstructured":"Duggan MC, et al. A phase I study of recombinant (r) vaccinia-CEA (6D)-TRICOM and rFowlpox-CEA (6D)-TRICOM vaccines with GM-CSF and IFN-\u03b1-2b in patients with CEA-expressing carcinomas. Cancer Immunol Immunother. 2016;65:1353\u20131364.","DOI":"10.1007\/s00262-016-1893-7"},{"key":"270_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/scbi.1998.0119","volume":"9","author":"S Hammarstrom","year":"1999","unstructured":"Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67\u201381. doi: 10.1006\/scbi.1998.0119 .","journal-title":"Semin Cancer Biol"},{"key":"270_CR7","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1111\/codi.12157","volume":"15","author":"J Park","year":"2013","unstructured":"Park J, Chang H, Kim B, Yeo H, Kim D. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer. Color Dis. 2013;15:e503\u201311.","journal-title":"Color Dis"},{"key":"270_CR8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.canlet.2014.10.019","volume":"356","author":"E Ahn","year":"2015","unstructured":"Ahn E, Kim H, Han KT, Sin J-I. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells\u2019 antigen presentation to Ag-specific CTLs in a colon cancer model. Cancer Lett. 2015;356:676\u201385.","journal-title":"Cancer Lett"},{"key":"270_CR9","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1080\/21645515.2015.1016669","volume":"11","author":"S-Y Lee","year":"2015","unstructured":"Lee S-Y, Sin J-I. MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model. Hum Vaccines Immunother. 2015;11:2012\u201320.","journal-title":"Hum Vaccines Immunother"},{"key":"270_CR10","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1016\/S0021-9258(18)98592-3","volume":"266","author":"AP Spicer","year":"1991","unstructured":"Spicer AP, Parry G, Patton S, Gendler SJ. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem. 1991;266:15099\u2013109.","journal-title":"J Biol Chem"},{"key":"270_CR11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1242\/dev.110.2.573","volume":"110","author":"JQ Huang","year":"1990","unstructured":"Huang JQ, Turbide C, Daniels E, Jothy S, Beauchemin N. Spatiotemporal expression of murine carcinoembryonic antigen (CEA) gene family members during mouse embryogenesis. Development. 1990;110:573\u201388.","journal-title":"Development"},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1017\/S003358350800468X","volume":"41","author":"AJ Schoeffler","year":"2008","unstructured":"Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys. 2008;41:41\u2013101. doi: 10.1017\/S003358350800468X .","journal-title":"Q Rev Biophys"},{"key":"270_CR13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s004120100140","volume":"110","author":"A Niimi","year":"2001","unstructured":"Niimi A, Suka N, Harata M, Kikuchi A, Mizuno S. Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA. Chromosoma. 2001;110:102\u201314.","journal-title":"Chromosoma"},{"key":"270_CR14","doi-asserted-by":"crossref","first-page":"33660","DOI":"10.1074\/jbc.273.50.33660","volume":"273","author":"P Grue","year":"1998","unstructured":"Grue P, et al. Essential mitotic functions of DNA topoisomerase IIalpha are not adopted by topoisomerase IIbeta in human H69 cells. J Biol Chem. 1998;273:33660\u20136.","journal-title":"J Biol Chem"},{"key":"270_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0378-1119(00)00040-8","volume":"245","author":"N Adachi","year":"2000","unstructured":"Adachi N, Nomoto M, Kohno K, Koyama H. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene. 2000;245:49\u201357.","journal-title":"Gene"},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/jcp.2006.038281","volume":"60","author":"K Al-Kuraya","year":"2007","unstructured":"Al-Kuraya K, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007;60:768\u201372. doi: 10.1136\/jcp.2006.038281 .","journal-title":"J Clin Pathol"},{"key":"270_CR17","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1158\/1078-0432.CCR-07-0686","volume":"13","author":"MH Andersen","year":"2007","unstructured":"Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007;13:5991\u20134. doi: 10.1158\/1078-0432.CCR-07-0686 .","journal-title":"Clin Cancer Res"},{"key":"270_CR18","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","volume":"14","author":"AC Mita","year":"2008","unstructured":"Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000\u20135. doi: 10.1158\/1078-0432.CCR-08-0746 .","journal-title":"Clin Cancer Res"},{"key":"270_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrc968","volume":"3","author":"DC Altieri","year":"2003","unstructured":"Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46\u201354. doi: 10.1038\/nrc968 .","journal-title":"Nat Rev Cancer"},{"key":"270_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00262-009-0795-3","volume":"59","author":"JS Park","year":"2010","unstructured":"Park JS, et al. Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope. Cancer Immunol Immunother. 2010;59:747\u201357. doi: 10.1007\/s00262-009-0795-3 .","journal-title":"Cancer Immunol Immunother"},{"key":"270_CR21","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/eji.200839098","volume":"39","author":"UB Hofmann","year":"2009","unstructured":"Hofmann UB, et al. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur J Immunol. 2009;39:1419\u201324. doi: 10.1002\/eji.200839098 .","journal-title":"Eur J Immunol"},{"key":"270_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1479-5876-2-19","volume":"2","author":"T Tsuruma","year":"2004","unstructured":"Tsuruma T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004;2:19. doi: 10.1186\/1479-5876-2-19 .","journal-title":"J Transl Med"},{"key":"270_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00262-013-1516-5","volume":"63","author":"V Lennerz","year":"2014","unstructured":"Lennerz V, et al. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014;63:381\u201394. doi: 10.1007\/s00262-013-1516-5 .","journal-title":"Cancer Immunol Immunother"},{"key":"270_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/1078-0432.CCR-14-0202","volume":"21","author":"Y Yoshitake","year":"2015","unstructured":"Yoshitake Y, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015;21:312\u201321. doi: 10.1158\/1078-0432.CCR-14-0202 .","journal-title":"Clin Cancer Res"},{"key":"270_CR25","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","volume":"19","author":"CL Slingluff Jr","year":"2013","unstructured":"Slingluff CL Jr, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013;19:4228\u201338. doi: 10.1158\/1078-0432.CCR-13-0002 .","journal-title":"Clin Cancer Res"},{"key":"270_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00262-012-1319-0","volume":"62","author":"S Phuphanich","year":"2013","unstructured":"Phuphanich S, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62:125\u201335. doi: 10.1007\/s00262-012-1319-0 .","journal-title":"Cancer Immunol Immunother"},{"key":"270_CR27","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/bit.24907","volume":"110","author":"YP Chuan","year":"2013","unstructured":"Chuan YP, et al. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng. 2013;110:2343\u201351.","journal-title":"Biotechnol Bioeng"},{"key":"270_CR28","doi-asserted-by":"publisher","first-page":"e66866","DOI":"10.1371\/journal.pone.0066866","volume":"8","author":"K Jemon","year":"2013","unstructured":"Jemon K, et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy. PLoS One. 2013;8:e66866. doi: 10.1371\/journal.pone.0066866 .","journal-title":"PLoS One"},{"key":"270_CR29","doi-asserted-by":"publisher","unstructured":"Li K, et al. Antigen incorporated in virus-like particles is delivered to specific dendritic cell subsets that induce an effective antitumor immune response in vivo. J Immunother. 2013;36:11\u20139. doi: 10.1097\/CJI.0b013e3182787f5e .","DOI":"10.1097\/CJI.0b013e3182787f5e"},{"key":"270_CR30","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1016\/j.vaccine.2008.07.074","volume":"26","author":"M Peacey","year":"2008","unstructured":"Peacey M, et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine. 2008;26:5334\u20137. doi: 10.1016\/j.vaccine.2008.07.074 .","journal-title":"Vaccine"},{"key":"270_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/icb.2010.161","volume":"89","author":"SJ Win","year":"2011","unstructured":"Win SJ, Ward VK, Dunbar PR, Young SL, Baird MA. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol. 2011;89:681\u20138. doi: 10.1038\/icb.2010.161 .","journal-title":"Immunol Cell Biol"},{"key":"270_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jconrel.2012.02.015","volume":"159","author":"SJ McKee","year":"2012","unstructured":"McKee SJ, et al. Virus-like particles and alpha-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. J Control Release. 2012;159:338\u201345. doi: 10.1016\/j.jconrel.2012.02.015 .","journal-title":"J Control Release"},{"key":"270_CR33","doi-asserted-by":"publisher","first-page":"e104523","DOI":"10.1371\/journal.pone.0104523","volume":"9","author":"F Al-Barwani","year":"2014","unstructured":"Al-Barwani F, Young SL, Baird MA, Larsen DS, Ward VK. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One. 2014;9:e104523. doi: 10.1371\/journal.pone.0104523 .","journal-title":"PLoS One"},{"key":"270_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","volume":"285","author":"IF Hermans","year":"2004","unstructured":"Hermans IF, et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods. 2004;285:25\u201340. doi: 10.1016\/j.jim.2003.10.017 .","journal-title":"J Immunol Methods"},{"key":"270_CR35","doi-asserted-by":"publisher","first-page":"e1003132","DOI":"10.1371\/journal.ppat.1003132","volume":"9","author":"X Wang","year":"2013","unstructured":"Wang X, et al. Atomic model of rabbit hemorrhagic disease virus by cryo-electron microscopy and crystallography. PLoS Pathog. 2013;9:e1003132. doi: 10.1371\/journal.ppat.1003132 .","journal-title":"PLoS Pathog"},{"key":"270_CR36","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/JVI.00314-10","volume":"84","author":"U Katpally","year":"2010","unstructured":"Katpally U, et al. High-resolution cryo-electron microscopy structures of murine norovirus 1 and rabbit hemorrhagic disease virus reveal marked flexibility in the receptor binding domains. J Virol. 2010;84:5836\u201341.","journal-title":"J Virol"},{"key":"270_CR37","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.4049\/jimmunol.172.3.1777","volume":"172","author":"T Storni","year":"2004","unstructured":"Storni T, et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol. 2004;172:1777\u201385.","journal-title":"J Immunol"},{"key":"270_CR38","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1128\/JVI.75.10.4752-4760.2001","volume":"75","author":"S Gerber","year":"2001","unstructured":"Gerber S, et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia Coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol. 2001;75:4752\u201360. doi: 10.1128\/JVI.75.10.4752-4760.2001 .","journal-title":"J Virol"},{"key":"270_CR39","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1016\/j.vaccine.2006.03.052","volume":"24","author":"SL Young","year":"2006","unstructured":"Young SL, et al. Transcutaneous vaccination with virus-like particles. Vaccine. 2006;24:5406\u201312. doi: 10.1016\/j.vaccine.2006.03.052 .","journal-title":"Vaccine"},{"key":"270_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1099\/0022-1317-82-4-787","volume":"82","author":"CD DeMaula","year":"2001","unstructured":"DeMaula CD, Jutila MA, Wilson DW, MacLachlan NJ. Infection kinetics, prostacyclin release and cytokine-mediated modulation of the mechanism of cell death during bluetongue virus infection of cultured ovine and bovine pulmonary artery and lung microvascular endothelial cells. J Gen Virol. 2001;82:787\u201394. doi: 10.1099\/0022-1317-82-4-787 .","journal-title":"J Gen Virol"},{"key":"270_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1743-422X-11-109","volume":"11","author":"M Matthaei","year":"2014","unstructured":"Matthaei M, et al. Comparative quantitative monitoring of rabbit haemorrhagic disease viruses in rabbit kittens. Virol J. 2014;11:109. doi: 10.1186\/1743-422X-11-109 .","journal-title":"Virol J"},{"key":"270_CR42","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626\u201334. doi: 10.1200\/JCO.2007.14.7116 .","journal-title":"J Clin Oncol"},{"key":"270_CR43","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757\u201365. doi: 10.1056\/NEJMoa0804385 .","journal-title":"N Engl J Med"},{"key":"270_CR44","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408\u201317. doi: 10.1056\/NEJMoa0805019 .","journal-title":"N Engl J Med"},{"key":"270_CR45","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1538-7445.AM2016-2232","volume":"76","author":"P Correale","year":"2016","unstructured":"Correale P, et al. Immune-inflammatory markers predict the outcome of metastatic colorectal cancer patients treated with the thymidylate synthase poly-epitope peptide (TSPP) vaccine: results from a multi-arm TSPP\/VAC phase Ib program. Cancer Res. 2016;76:2232.","journal-title":"Cancer Res"},{"key":"270_CR46","doi-asserted-by":"crossref","first-page":"012","DOI":"10.23937\/2378-3419\/2\/1\/1012","volume":"2","author":"F Satomi","year":"2015","unstructured":"Satomi F, Shima H, Mizuguchi T, Torigoe T, Kutomi G, Phase I. Clinical study of survivin-derived peptide vaccine for patients with advanced gastrointestinal cancers. Int J Cancer Clin Res. 2015;2:012.","journal-title":"Int J Cancer Clin Res"},{"key":"270_CR47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00918679","volume":"11","author":"HM Shepard","year":"1991","unstructured":"Shepard HM, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11:117\u201327.","journal-title":"J Clin Immunol"},{"key":"270_CR48","first-page":"1829","volume":"9","author":"RJ Pietras","year":"1994","unstructured":"Pietras RJ, et al. Antibody to HER-2\/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829\u201338.","journal-title":"Oncogene"},{"key":"270_CR49","doi-asserted-by":"publisher","first-page":"8804","DOI":"10.1038\/sj.onc.1206028","volume":"21","author":"M Huang","year":"2002","unstructured":"Huang M, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002;21:8804\u201316. doi: 10.1038\/sj.onc.1206028 .","journal-title":"Oncogene"},{"key":"270_CR50","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1538-7445.AM2016-2235","volume":"76","author":"AMA Tryggestad","year":"2016","unstructured":"Tryggestad AMA, et al. Clinical results of a phase I\/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin. Cancer Res. 2016;76:2235.","journal-title":"Cancer Res"},{"key":"270_CR51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","volume":"166","author":"M Murahashi","year":"2016","unstructured":"Murahashi M, et al. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016;166:48\u201358.","journal-title":"Clin Immunol"},{"key":"270_CR52","doi-asserted-by":"crossref","unstructured":"Maurel J. et al.\u00a0Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients. ASCO Annual Meeting Proceedings.\u00a02015;33:3048.","DOI":"10.1200\/jco.2015.33.15_suppl.3048"},{"key":"270_CR53","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.4049\/jimmunol.170.3.1231","volume":"170","author":"MK Slifka","year":"2003","unstructured":"Slifka MK, et al. Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J Immunol. 2003;170:1231\u20139.","journal-title":"J Immunol"},{"key":"270_CR54","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/JVI.76.9.4251-4259.2002","volume":"76","author":"F Rodriguez","year":"2002","unstructured":"Rodriguez F, Harkins S, Slifka MK, Whitton JL. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol. 2002;76:4251\u20139.","journal-title":"J Virol"},{"key":"270_CR55","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1016\/S0264-410X(01)00179-7","volume":"19","author":"K Peter","year":"2001","unstructured":"Peter K, Men Y, Pantaleo G, Gander B, Corradin G. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine. 2001;19:4121\u20139.","journal-title":"Vaccine"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0270-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T04:35:56Z","timestamp":1659328556000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0270-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0270-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"article-number":"69"}}